Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482794 · ClinicalTrials.gov registry record
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
A clinical trial of Antiphospholipid Syndrome, sponsored by Duke University.
- Recruiting
- Registry status
- 2,800
- Enrollment target
- 1
- Study location
NCT00482794 is a study of Antiphospholipid Syndrome that is actively recruiting participants, run by Duke University. The registered enrollment target is 2,800 participants, above the 984-participant average among 6 other Antiphospholipid Syndrome trials with a reported enrollment target (185% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00482794, a study of Antiphospholipid Syndrome, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 2,800 participants
- Enrollment target
- 1
- Study location
Study Summary
Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk for the formation of blood clots in the lungs or deep veins of the legs, stroke, heart attack, and recurrent miscarriages. It is possible that some people with APS have a genetic predisposition for developing the syndrome. This study will use a genetic strategy to identify potential inherited risk factors for the development of APS by recruiting people with APS who have family members also affected by the syndrome or by another autoimmune disorder, such as lupus or rheumatoid arthritis.
Conditions Studied
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,800 participants |
| Start Date | 2006-06 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482794
The ClinicalTrials.gov registry entry for NCT00482794 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 984-participant average among 6 other Antiphospholipid Syndrome trials with a reported enrollment target (185% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Antiphospholipid Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00482794 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00482794 about?
NCT00482794 is a clinical study titled "Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome". Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk f...
What is the current status of trial NCT00482794?
This trial is currently recruiting. The enrollment target is 2,800 participants. The study started on 2006-06. Estimated completion is 2028-03.
What conditions does trial NCT00482794 study?
This clinical trial studies the following conditions: Antiphospholipid Syndrome.
Who is sponsoring clinical trial NCT00482794?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00482794 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antiphospholipid Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Patient Registry and Biorepository
RECRUITING
-
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
RECRUITING
-
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
RECRUITING
-
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
COMPLETED · Phase 2
-
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
COMPLETED
-
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.